Perfusion CT Changes in Liver Metastases from Pancreatic Neuroendocrine Tumors During Everolimus Treatment.
To evaluate modifications of perfusional parameters assessed by perfusion computed tomography (P-CT) of liver metastases (LM) from pancreatic neuroendocrine tumors (PanNETs) during everolimus treatment.



All patients with LMs from G1-2 PanNETs undergoing everolimus treatment between January 2013 and January 2015 were prospectively evaluated with P-CT at baseline, and after 2 and 4 months of therapy. Size, perfusion, blood volume (BV), peak enhancement intensity (PEI) and time to peak for each lesion were calculated.



A total of 33 LMs in nine patients with G1-2 PanNETs were prospectively evaluated: 23/33 (69.7%) were responders, 10/33 (30.3%) were non-responders. Among perfusional parameters, only numerical peak enhancement intensity values significantly differed between the two groups at baseline (p=0.043). BV increase was the most significant perfusional modification identifying responding lesions, even at an early stage of treatment, with a high positive predictive value (89.47%).



P-CT seems to be useful for prediction of response to everolimus of LMs from PanNETs.
Department of Diagnostic and Public Health, Institute of Radiology, G.B. Rossi Hospital, University of Verona, Verona, Italy mirko.donofrio@univr.it.
Mirko
M
D'Onofrio
Department of Oncology, G.B. Rossi Hospital, University of Verona, Verona, Italy.
Sara
S
Cingarlini
Department of Oncology, G.B. Rossi Hospital, University of Verona, Verona, Italy.
Silvia
S
Ortolani
Department of Diagnostic and Public Health, Institute of Radiology, G.B. Rossi Hospital, University of Verona, Verona, Italy.
Stefano
S
Crosara
Department of Radiology, Pederzoli Hospital, Peschiera del Garda, Verona, Italy.
Riccardo
R
DE Robertis
Department of Internal Medicine, G.B. Rossi Hospital, University of Verona, Verona, Italy.
Paola
P
Vallerio
Department of Oncology, G.B. Rossi Hospital, University of Verona, Verona, Italy.
Elisabetta
E
Grego
Department of Diagnostic and Public Health, Institute of Radiology, G.B. Rossi Hospital, University of Verona, Verona, Italy.
Valentina
V
Ciaravino
Department of Hepato-biliary Surgery, G.B. Rossi Hospital, University of Verona, Verona, Italy.
Andrea
A
Ruzzenente
Department of Pancreatic Surgery, G.B. Rossi Hospital, University of Verona, Verona, Italy.
Luca
L
Landoni
Department of Pathology, G.B. Rossi Hospital, University of Verona, Verona, Italy.
Aldo
A
Scarpa
Department of Pancreatic Surgery, G.B. Rossi Hospital, University of Verona, Verona, Italy.
Claudio
C
Bassi
Department of Oncology, G.B. Rossi Hospital, University of Verona, Verona, Italy.
Giampaolo
G
Tortora
D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D014408:Biomarkers, Tumor; D003287:Contrast Media; D000068338:Everolimus / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008099:Liver / Q000473:pathology; D008113:Liver Neoplasms / Q000000981:diagnostic imaging*; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D018358:Neuroendocrine Tumors / Q000000981:diagnostic imaging*; D010190:Pancreatic Neoplasms / Q000000981:diagnostic imaging*; D010477:Perfusion; D011446:Prospective Studies; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D003287:Contrast Media; D000068338:Everolimus
Perfusion CT; everolimus; pancreatic neuroendocrine tumor; perfusion; predictive biomarkers